S
Sana Health
Manufactures a smart sleep mask to aide insomniacs
About Sana Health
Sana Health operates in the medical technology sector, focusing on non-pharmaceutical solutions for chronic pain, mental well-being, and sleep issues. The company's genesis is deeply rooted in the personal story of its founder and CEO, Richard Hanbury. In 1992, at the age of 19, Hanbury survived a jeep crash in Yemen that resulted in a severe spinal cord injury and excruciating, life-threatening nerve pain. Faced with a grim prognosis, he embarked on a decades-long journey to find a solution for his own suffering, which led to the creation of the Sana device. This personal mission to overcome his pain forms the core of the company's vision. Hanbury's background includes an MBA from the Wharton School and prior experience at McKinsey.
The business is centered around its primary product, the Sana device, a neuromodulation platform. This non-invasive wearable resembles a mask and uses coordinated pulses of light and sound to guide the user's brain into a state of deep relaxation, mimicking the effects of long-term meditation. A key feature is a heart rate variability (HRV) sensor that creates a biofeedback loop, personalizing the audiovisual patterns to deepen the user's state of relaxation. This technology is designed to help users accelerate physical recovery, improve mental well-being, and achieve more restful sleep. The company targets individuals suffering from conditions like neuropathic pain, fibromyalgia, and PTSD.
Sana Health's business model revolves around the development and future sale of this medical device, contingent on regulatory clearance. The company is actively engaged in clinical trials to validate its technology's efficacy for various conditions. Significant milestones include receiving a Breakthrough Device Designation from the FDA and securing a $3.4 million grant from the U.S. Department of Defense to conduct a pivotal study on PTSD. Sana Health has submitted data from its neuropathic pain study to the FDA for market approval and anticipates a decision between late 2024 and mid-2025. The company has pursued a strategy of securing grants and raising capital through funding rounds to finance its extensive research and development and navigate the FDA approval process.
Source: Dealroom company dataNews
Open roles
Sana Health in the Louisville ecosystem
The Sana Health office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed8 investors entered at this stage
SOSV
Hax
Founders Fund
Maveron
European Innovation Council
HealthTech CapitalNCL Technology Ventures
WPSS.bio
Series A1 investor entered at this stage
Noetic Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sana Health on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sana Health on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

